Antidepressive Agents

• 

  Subject Areas on Research

  • 5-HTTLPR and use of antidepressants after colorectal cancer including a meta-analysis of 5-HTTLPR and depression after cancer. 
  • A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. 
  • A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. 
  • A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? 
  • A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 
  • A combined treatment approach to anxiety in the medically ill. 
  • A comparison of alternative assessments of depressive symptom severity: a pilot study. 
  • A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. 
  • A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. 
  • A double-blind comparison of bupropion and amitriptyline in depressed inpatients. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. 
  • A global logrank test for adaptive treatment strategies based on observational studies. 
  • A history of the concept of atypical depression. 
  • A longitudinal evaluation of adolescent depression and adult obesity. 
  • A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. 
  • A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 
  • A practical approach to the early identification of antidepressant medication non-responders. 
  • A preliminary metabolomic analysis of older adults with and without depression. 
  • A prescription for unemployment? Recessions and the demand for mental health drugs. 
  • A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. 
  • A randomized controlled trial of paroxetine for noncardiac chest pain. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. 
  • A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. 
  • A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. 
  • A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. 
  • A systematic review of treatments for refractory depression in older people. 
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 
  • Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. 
  • Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. 
  • Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. 
  • Adinazolam sustained-release treatment of panic disorder: a double-blind study. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • Advances in opioid antagonist treatment for opioid addiction. 
  • Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. 
  • Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. 
  • Algorithms for optimizing the treatment of depression: making the right decision at the right time. 
  • Alprazolam in bipolar-I depressions. 
  • Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. 
  • American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. 
  • An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • An overview of the clinical rationale for advancing gender-related psychopharmacology and drug abuse research. 
  • Angiotensin receptor gene polymorphisms and 2-year change in hyperintense lesion volume in men. 
  • Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. 
  • Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors. 
  • Antidepressant Use in a 3- to 12-Year Follow-up of Anxious Youth: Results from the CAMELS Trial. 
  • Antidepressant Use, Depression, and Poor Cardiovascular Outcomes: The Chicken or the Egg?: Comment on "Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women's Health Initiative Study". 
  • Antidepressant actions of histone deacetylase inhibitors. 
  • Antidepressant effects of nicotine in an animal model of depression. 
  • Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. 
  • Antidepressant medication use [corrected] and risk of ovarian cancer. 
  • Antidepressant medication use in palliative care. 
  • Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. 
  • Antidepressant response to electroconvulsive therapy is sustained after catecholamine depletion. 
  • Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. 
  • Antidepressant therapy in patients with ischemic heart disease. 
  • Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. 
  • Antidepressant use and the risk of myocardial infarction. 
  • Antidepressant use by race. 
  • Antidepressant use in the elderly: association with demographic characteristics, health-related factors, and health care utilization. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. 
  • Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism. 
  • Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. 
  • Antidepressants in chronic pain syndromes. 
  • Antidepressants in inflammatory bowel disease. 
  • Are Cosmetic Procedures Comparable to Antidepressive Medication for Quality-of-Life Improvements? A Systematic Review and Controlled Meta-Analysis. 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Are psychiatrists' characteristics related to how they care for depression in the medically ill? Results from a national case-vignette survey. 
  • Assessing anxious features in depressed outpatients. 
  • Assessing the effect of Measurement-Based Care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. 
  • Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. 
  • Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. 
  • Atypical depression: a comprehensive review. 
  • Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment. 
  • Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. 
  • Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. 
  • Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. 
  • Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. 
  • Behavioral effects of short-term administration of lithium and valproic acid in rats. 
  • Behavioral treatment of obsessive-compulsive neurosis. 
  • Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. 
  • Benzodiazepines as antidepressants: does GABA play a role in depression? 
  • Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. 
  • Best clinical practice: guidelines for managing major depression in primary medical care. 
  • Better, Faster, Safer: Exploring Biomarkers of Response to Transform Electroconvulsive Therapy. 
  • Biological and cognitive predictors of response to acute treatment in depressed outpatients. 
  • Biological and social predictors of long-term geriatric depression outcome. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Bipolar Depression: Pregnancy, Postpartum, and Lactation. 
  • Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. 
  • Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 
  • Bupropion dosing recommendations. 
  • Bursts and the efficacy of selective serotonin reuptake inhibitors. 
  • Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 
  • Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives. 
  • Case report of treatment of severe mood disorder in an inpatient setting: when less is more. 
  • Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. 
  • Catching up on health outcomes: the Texas Medication Algorithm Project. 
  • Changes in HIV Outcomes Following Depression Care in a Resource-Limited Setting: Results from a Pilot Study in Bamenda, Cameroon. 
  • Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Cholinergic-adrenergic hypothesis of mania and depression. 
  • Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. 
  • Chronic pain and depression. 
  • Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. 
  • Circadian Preference as a Moderator of Depression Outcome Following Cognitive Behavioral Therapy for Insomnia Plus Antidepressant Medications: A Report From the TRIAD Study. 
  • Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. 
  • Clinical and radiological characteristics of early versus late mild cognitive impairment in patients with comorbid depressive disorder. 
  • Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. 
  • Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. 
  • Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. 
  • Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. 
  • Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. 
  • Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. 
  • Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. 
  • Clinical outcomes of older depressed patients with and without comorbid neuroticism. 
  • Clinical practice guidelines for managing major depression in primary care practice. Implications for psychologists. U.S. Public Health Service Agency for Health Care Policy and Research. 
  • Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. 
  • Clinical trial evidence for treatment of depression in heart failure. 
  • Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. 
  • Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. 
  • Cognitive improvement following treatment in late-life depression: relationship to vascular risk and age of onset. 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. 
  • Combining antidepressant medications: a good idea? 
  • Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. 
  • Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. 
  • Comorbidities in patients with all-positive symptoms on sinonasal outcomes test quality-of-life instrument. 
  • Comorbidity and depression treatment. 
  • Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. 
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. 
  • Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. 
  • Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. 
  • Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. 
  • Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. 
  • Competing demands: Does care for depression fit in primary care? 
  • Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. 
  • Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". 
  • Consensus guidelines in the treatment of major depressive disorder. 
  • Consensus statement on depression, anxiety, and oncology. 
  • Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. 
  • Contemporary management of comorbid anxiety and depression in geriatric patients. 
  • Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. 
  • Correlates of remission in primary care patients treated for minor depression. 
  • Cortical thickness predicts remission of depression with antidepressants in patients with late-life depression and cognitive impairment. 
  • Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. 
  • Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats. 
  • DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. 
  • Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 
  • Datapoints: Use of medications and counseling for depression by Asian and multiple-race adolescents aged 12-17 years. 
  • DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. 
  • Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. 
  • Depression after myocardial infarction. 
  • Depression and antidepressant use after stroke and transient ischemic attack. 
  • Depression and cardiac risk. 
  • Depression and cognition in the elderly. 
  • Depression and insomnia in women. 
  • Depression and insulin resistance: applications to polycystic ovary syndrome. 
  • Depression and ischemic heart disease. 
  • Depression and ischemic heart disease: what have we learned from clinical trials? 
  • Depression and ischemic heart disease: what have we learned so far and what must we do in the future? 
  • Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. 
  • Depression in late life. 
  • Depression in long-term care. 
  • Depression in the elderly. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression treatment in a sample of 1,801 depressed older adults in primary care. 
  • Depression, IV: STAR*D treatment trial for depression. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Depression, post-traumatic stress disorder, and dry eye syndrome: a study utilizing the national United States Veterans Affairs administrative database. 
  • Depressive Symptoms and Risk of Cardiovascular Events in Blacks: Findings From the Jackson Heart Study. 
  • Depressive characteristics of FSL rats: involvement of central nicotinic receptors. 
  • Depressive disorders in older medical inpatients. 
  • Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 
  • Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. 
  • Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. 
  • Diagnostic Accuracy of Screening Tests and Treatment for Post-Acute Coronary Syndrome Depression: A Systematic Review. 
  • Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. 
  • Differential effects of the antidepressant mirtazapine on amphetamine- and dizocilpine-induced PPI deficits. 
  • Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. 
  • Difficult behaviors in long-term care patients with dementia. 
  • Disparities in Depressive Symptoms and Antidepressant Treatment by Gender and Race/Ethnicity among People Living with HIV in the United States. 
  • Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. 
  • Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. 
  • Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. 
  • Does antidepressant therapy improve cognition in elderly depressed patients? 
  • Does medication adherence following a copayment increase differ by disease burden? 
  • Does minocycline have antidepressant effect? 
  • Does neurotropin-3 have a therapeutic implication in major depression? 
  • Does pretreatment anxiety predict response to either bupropion SR or sertraline? 
  • Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. 
  • Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. 
  • Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. 
  • Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. 
  • Duloxetine: an emerging evidence for fibromyalgia. 
  • Durability of antidepressant response to vagus nerve stimulation (VNS). 
  • Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. 
  • Dysfunctional attitudes in depressed patients before and after clinical treatment and in normal control subjects. 
  • Dyspepsia. 
  • EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. 
  • ERICH3: vesicular association and antidepressant treatment response. 
  • Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. 
  • Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. 
  • Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. 
  • Eating disorders. 
  • Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. 
  • Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. 
  • Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. 
  • Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. 
  • Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. 
  • Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. 
  • Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. 
  • Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. 
  • Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. 
  • Effectiveness of chromium in atypical depression: a placebo-controlled trial. 
  • Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. 
  • Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study. 
  • Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. 
  • Effects of amphetamines and small related molecules on recovery after stroke in animals and man. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. 
  • Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy. 
  • Effects of exercise training on older patients with major depression. 
  • Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. 
  • Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. 
  • Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. 
  • Efficacy and safety of St. John's wort for the treatment of major depression. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. 
  • Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. 
  • Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. 
  • Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy of treatments for major depression. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. 
  • Efficient trial designs to reduce placebo requirements. 
  • Electric field causes volumetric changes in the human brain. 
  • Electroconvulsive Therapy Pulse Amplitude and Clinical Outcomes. 
  • Electroconvulsive therapy, electric field, neuroplasticity, and clinical outcomes. 
  • Electroconvulsive therapy: how effective is it? 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice. 
  • Emergent anxiety after antidepressant initiation: a retrospective cohort study of Veterans Affairs Health System patients with depression. 
  • Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. 
  • Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. 
  • Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. 
  • Escitalopram related edema in a patient with Hashimoto's thyroiditis. 
  • Ethnic differences in the treatment of depression in patients with ischemic heart disease. 
  • Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. 
  • Evidence-based treatment of psychiatric disorders with comorbid medical illnesses: the need for large simple clinical trials. 
  • Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. 
  • Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. 
  • Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 
  • Exercise and pharmacotherapy in the treatment of major depressive disorder. 
  • Exercise fails to improve neurocognition in depressed middle-aged and older adults. 
  • Exercise therapy for depression in middle-aged and older adults: predictors of early dropout and treatment failure. 
  • Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. 
  • Exposure to SSRI-type antidepressants increases righting time in the marine snail Ilyanassa obsoleta. 
  • Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. 
  • Factors associated with antidepressant, anxiolytic, and other psychotropic medication use to treat psychiatric symptoms in the city of São Paulo, Brazil. 
  • Factors that differentiate early vs. later onset of major depression disorder. 
  • Family history of depression and therapeutic outcome: findings from STAR*D. 
  • Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 
  • Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. 
  • Fiber tract-specific white matter lesion severity Findings in late-life depression and by AGTR1 A1166C genotype. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Folate and unipolar depression. 
  • Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. 
  • Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. 
  • Frontal white matter anisotropy and antidepressant remission in late-life depression. 
  • Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 
  • Functional Dyspepsia. 
  • Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. 
  • Further studies on platelet serotonin transporter binding in depression. 
  • Gender differences in antidepressant and activating-drug effects on self-perceptions 
  • Gender, depressive subtypes, and gender-age effects on antidepressant response: Hormonal hypotheses 
  • Generalized anxiety disorder and irritable bowel syndrome. 
  • Generalized anxiety disorder. An important clinical concern. 
  • Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. 
  • Goodness-of-fit tests for GEE modeling with binary responses. 
  • Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. 
  • Hippocampal volume and antidepressant response in geriatric depression. 
  • Hippocampus atrophy and the longitudinal course of late-life depression. 
  • Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. 
  • I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale. 
  • Identifying depression in primary care: a literature synthesis of case-finding instruments. 
  • Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans. 
  • Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. 
  • Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. 
  • Impact of hospital type II violent events: use of psychotropic drugs and mental health services. 
  • Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. 
  • Impacts of depression and emotional distress on cardiac disease. 
  • Impaired cholecystokinin secretion in bulimia nervosa. 
  • Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. 
  • Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial. 
  • Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care. 
  • Improving Depression Outcome by Patient-Centered Medical Management. 
  • Improving depression care for older, minority patients in primary care. 
  • Improving depression outcomes in older adults with comorbid medical illness. 
  • Improving primary care for depression in late life: the design of a multicenter randomized trial. 
  • Improving the chance of recovery from the short- and long-term consequences of depression. 
  • Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. 
  • Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Indicators of anxiety and depression in women with the fragile X premutation: assessment of a clinical sample. 
  • Indicators of pretreatment suicidal ideation in adults with major depressive disorder. 
  • Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. 
  • Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatrist physicians. 
  • Insight and treatment outcome in obsessive-compulsive disorder. 
  • Insured and non-insured depressed outpatients: how do they compare? 
  • International consensus statement on major depressive disorder. 
  • Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series. 
  • Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. 
  • Is there a definition of remission in late-life depression that predicts later relapse? 
  • Isn't It About Time to Employ Measurement-Based Care in Practice? 
  • Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. 
  • Ketamine for treatment-resistant depression: ready or not for clinical use? 
  • Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. 
  • Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. 
  • Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 
  • Late-life depression: how to treat patients with comorbid chronic illness. Interview by Alice V. Luddington. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Limitations in efficacy of antidepressant monotherapy. 
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 
  • Lobar distribution of lesion volumes in late-life depression: the Biomedical Informatics Research Network (BIRN). 
  • Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population. 
  • Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. 
  • Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. 
  • Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. 
  • Major depression, antidepressant use, and male and female fertility. 
  • Major depressive disorder treatment guidelines in America and Europe. 
  • Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients. 
  • Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. 
  • Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. 
  • Measurement of depression treatment among patients receiving HIV primary care: Whither the truth? 
  • Measurement-based care in psychiatric practice: a policy framework for implementation. 
  • Medication adherence in combat veterans with traumatic brain injury. 
  • Meeting the needs of primary care physicians: a guide to content for programs on depression. 
  • Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. 
  • Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. 
  • Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. 
  • Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. 
  • Milnacipran: beyond a role of antidepressant. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Minor depression and physical outcome trajectories in heart failure and pulmonary disease. 
  • Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. 
  • Mood disorders and chronic obstructive pulmonary disease: current research and future needs. 
  • Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. 
  • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. 
  • National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder. 
  • Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. 
  • Neural mechanisms of cognitive reappraisal in remitted major depressive disorder. 
  • Neurocognitive correlates of response to treatment in late-life depression. 
  • Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. 
  • New Developments in Insomnia Medications of Relevance to Mental Health Disorders. 
  • New concepts in the diagnosis and management of depression. 
  • New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. 
  • Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. 
  • Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. 
  • Nonpharmacologic treatments for depression in patients with coronary heart disease. 
  • One-year change in anterior cingulate cortex white matter microstructure: relationship with late-life depression outcomes. 
  • One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. 
  • Onset of alcohol or substance use disorders following treatment for adolescent depression. 
  • Outpatient utilization patterns of integrated and split psychotherapy and pharmacotherapy for depression. 
  • Overview of psychiatric disorders and the role of newer antidepressants. 
  • Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. 
  • Panic disorder: making clinical sense of the latest research. 
  • Parental marital discord and treatment response in depressed adolescents. 
  • Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. 
  • Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. 
  • Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease. 
  • Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. 
  • Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. 
  • Pharmacological agents to treat severe neuropsychiatric symptoms in major neurocognitive disorders. 
  • Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. 
  • Pharmacotherapy of generalized anxiety disorder. 
  • Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. 
  • Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. 
  • Physician office visits of adults for anxiety disorders in the United States, 1985-1998. 
  • Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Polysomnographic findings in recently drug-free and clinically remitted depressed patients. 
  • Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. 
  • Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. 
  • Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. 
  • Potential effects of common drugs on stroke recovery. 
  • Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. 
  • Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 
  • Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. 
  • Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. 
  • Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. 
  • Predictors of antidepressant use among older adults: have they changed over time? 
  • Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. 
  • Predictors of depression outcomes in medical inpatients with chronic pulmonary disease. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of recurrence in remitted late-life depression. 
  • Prefrontal neuropsychological predictors of treatment remission in late-life depression. 
  • Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. 
  • Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study. 
  • Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder. 
  • Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. 
  • Prevalence of depression and its treatment in an elderly population: the Cache County study. 
  • Primary care physicians' and psychiatrists' approaches to treating mild depression. 
  • Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. 
  • Progression of subcortical ischemic disease from vascular depression to vascular dementia. 
  • Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. 
  • Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. 
  • Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. 
  • Provider characteristics related to antidepressant use in older people. 
  • Providers' attitudes towards treating depression and self-reported depression treatment practices in HIV outpatient care. 
  • Psychological discomfort and mental illness in patients with AIDS: implications for home care. 
  • Psychopharmacological treatment for very young children: contexts and guidelines. 
  • Psychosocial and clinical predictors of unipolar depression outcome in older adults. 
  • Psychosocial context of antidepressant response. 
  • Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? 
  • Psychotropic drug use in late life: a diverse look at an expanding field. 
  • Psychotropic drugs on general medical and surgical wards of a teaching hospital. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • RU486 in depression. 
  • Racial differences in antidepressant treatment preceding suicide in a Medicaid population. 
  • Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. 
  • Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Rational treatment choices for non-major depressions in primary care: an evidence-based review. 
  • Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). 
  • Rationale, design, and baseline data for a multicenter randomized clinical trial comparing depression screening strategies after acute coronary syndrome: The comparison of depression identification after acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. 
  • Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. 
  • Recent advances in poststroke depression. 
  • Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relapse of depressive symptoms after discontinuing sertraline. 
  • Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. 
  • Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. 
  • Relationship of pharmaceutical promotion to antidepressant switching and adherence: a retrospective cohort study. 
  • Religiosity and remission of depression in medically ill older patients. 
  • Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. 
  • Remissions in maternal depression and child psychopathology: a STAR*D-child report. 
  • Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. 
  • Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. 
  • Research issues in the study of difficult-to-treat depression. 
  • Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Response inhibition predicts poor antidepressant treatment response in very old depressed patients. 
  • Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? 
  • STAR*D: revising conventional wisdom. 
  • STAR*D: what have we learned? 
  • Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. 
  • Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. 
  • Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. 
  • Scopolamine sleep treatment in private practise. 
  • Secondary agoraphobia: two case reports. 
  • Seizures and bupropion: a review. 
  • Selecting methodologies for the evaluation of differences in time to response between antidepressants. 
  • Self-rated global measure of the frequency, intensity, and burden of side effects. 
  • Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. 
  • Sertraline as a first-line treatment for cholestatic pruritus. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline in children and adolescents with social anxiety disorder: an open trial. 
  • Sexual functioning of men and women with severe obesity before bariatric surgery. 
  • Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. 
  • Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. 
  • Sleep therapeutics and neuropsychiatric illness. 
  • Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. 
  • Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. 
  • Special aspects of neuropsychiatric illness in women: With a focus on depression 
  • Speed of response to electroconvulsive therapy compared with ketamine. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Star-D: lessons learned and future implications. 
  • Strategies and tactics in the management of maintenance treatment for depressed patients. 
  • Strategies and tactics in the treatment of chronic depression. 
  • Strengthening clinical effectiveness trials: equipoise-stratified randomization. 
  • Stress-induced muscle and cutaneous hyperalgesia: differential effect of milnacipran. 
  • Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. 
  • Study protocol for evaluating the effectiveness of depression management on gylcaemic control in non-communicable diseases clinics in Malawi. 
  • Subsyndromal and syndromal depressive symptoms among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study. 
  • Suicidality as a possible side effect of antidepressant treatment. 
  • Suicide risk analysis among patients assigned to psychotropics and placebo. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • Targeting treatments for depression: what can our patients tell us? 
  • Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. 
  • The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. 
  • The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States. 
  • The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. 
  • The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. 
  • The Natural Course of Adolescent Depression Treatment in the Primary Care Setting. 
  • The STAR*D study: treating depression in the real world. 
  • The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. 
  • The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. 
  • The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. 
  • The Use of Antidepressants in Bipolar Depression. 
  • The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). 
  • The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. 
  • The changing perspective on chronic insomnia management. 
  • The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. 
  • The cost consequences of treatment-resistant depression. 
  • The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. 
  • The effectiveness of depression care management on diabetes-related outcomes in older patients. 
  • The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. 
  • The effects of nefazodone on sleep architecture in depression. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. 
  • The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. 
  • The pharmacologic management of insomnia in patients with HIV. 
  • The relationship between fibromyalgia and major depressive disorder: a comprehensive review. 
  • The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. 
  • The sea urchin embryo as a model for mammalian developmental neurotoxicity: ontogenesis of the high-affinity choline transporter and its role in cholinergic trophic activity. 
  • The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. 
  • The treatment of primary insomnia. 
  • The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? 
  • The undertreatment of dysthymia. 
  • The use of analgesics in the management of pain in rheumatic diseases. 
  • The use of pharmacotherapies for smoking cessation during pregnancy. 
  • The use of placebos in unipolar major depression: the current status. 
  • Thyroid hormones affect recovery from depression during antidepressant treatment. 
  • Tiagabine in treatment refractory bipolar disorder: a clinical case series. 
  • Time-to-remission from geriatric depression: psychosocial and clinical factors. 
  • Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales. 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. 
  • Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. 
  • Treating cognitive impairment in depression: an unmet need. 
  • Treating depression within the HIV "medical home": a guided algorithm for antidepressant management by HIV clinicians. 
  • Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. 
  • Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. 
  • Treatment considerations for patients with neuropathic pain and other medical comorbidities. 
  • Treatment considerations for the depressed geriatric medical patient. 
  • Treatment course with antidepressant therapy in late-life depression. 
  • Treatment of depression in the medically ill. 
  • Treatment of depression--newer pharmacotherapies. 
  • Treatment of depression. 
  • Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. 
  • Treatment of older adults with co-morbid personality disorder and depression: a dialectical behavior therapy approach. 
  • Treatment of post-stroke depression with antidepressants. 
  • Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues. 
  • Understanding the biological basis of psychiatric disease: What's next? 
  • Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. 
  • Use of antidepressants for the treatment of psychiatric illnesses. 
  • Use of antidepressants in medically ill older patients. 
  • Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. 
  • Use of the light/dark test for anxiety in adult and adolescent male rats. 
  • Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. 
  • Variability in sleep disturbance, physical activity and quality of life by level of depressive symptoms in women with Type 2 diabetes. 
  • Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. 
  • Vascular nutritional correlates of late-life depression. 
  • Vmat2 heterozygous mutant mice display a depressive-like phenotype. 
  • What are the new treatments for bipolar disorder? 
  • What is the overlap between subjective and objective cognitive impairments in MDD? 
  • What predicts attrition in second step medication treatments for depression?: a STAR*D Report. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
  • When at first you don't succeed: sequential strategies for antidepressant nonresponders. 
  • Which depressions respond to placebo? 
  • White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study. 
  • White matter hyperintensity progression and late-life depression outcomes. 
  • World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. 
  • Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Nieuwsma, Jason A, Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine